Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGEND-109
- Development stage
- Preclinical
- Lead developer
- Regend Therapeutics
- Modality
- Cell Therapies
- Administration
- Parenteral
01
Overview
**REGEND-109** is an investigational **cell therapy** developed by **Suzhou Genmedicine Medical Technology** for **chronic obstructive pulmonary disease**. The product's active component has been described as **lung progenitor cells**, and its proposed mechanism is **cell replacement**, aiming to restore or regenerate damaged pulmonary tissue rather than modulate a single defined molecular target. Based on the information provided, REGEND-109 is a regenerative medicine program in the cell and gene therapy category, with no identified brand name, approval, or conventional drug-target pairing reported.
- Other names
- lung progenitor cells
Beyond the preview
Go deeper on REGEND-109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGEND-109.